Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar drug HanDaYuan has received additional indication approvals from China’s National Medical Products Administration (NMPA). HanDaYuan, a biosimilar version of AbbVie’s Humira (adalimumab), an autoimmune disease therapy, is now approved to treat a wider range of conditions including polyarthritic juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease, and pediatric Crohn’s disease.
First approved in China in December 2020, HanDaYuan has been gaining market approvals to treat an array of autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and uveitis. The commercialization of HanDaYuan in China is managed by Wanbang Biopharmaceuticals Co., Ltd. Other biosimilars to Humira that have been approved in China are offered by a competitive field of companies including Bio-Thera, BioRay, Sinocelltech, Sino Bio, Junshi, Mabwell, and Innovent.- Flcube.com
